Clinical Trials Sponsored by Solace Therapeutics, Inc.

Total 2995 results

Nohla Therapeutics, Inc.

Terminated

NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH)

Leukemia, Myeloid, Acute

United States, Korea, Republic of, Australia
Axsome Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder (STRIDE-1)

Treatment Resistant Major Depressive Disorder

United States
Vasomune Therapeutics, Inc.

Completed

A First-in-Human Study of AV-001 in Healthy Subjects

Covid19 | ARDS | Covid19-associated ARDS

United States
Esperion Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Dyslipidemia

United States
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Esperion Therapeutics, Inc.

Completed

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

United States
Cyclo Therapeutics, Inc.

Completed

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

Niemann-Pick Disease, Type C1

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19

Covid19
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

COPD

United States, Austria, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Peru, Russian Federation, Hungary, China, Taiwan, Australia, Japan, Argentina, South Africa, Belgium, Czechia, Serbia, Poland, Mexico, New... and more
Travere Therapeutics, Inc.

Terminated

Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants (PKAN)

Pantothenate Kinase-Associated Neurodegeneration

United States, Canada, Czechia, France, Germany, Italy, Norway, Poland, Spain
Lisata Therapeutics, Inc.

Completed

ACT34-CMI -- Adult Autologous CD34+ Cells

Myocardial Ischemia

United States
Sarepta Therapeutics, Inc.

Completed

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)

United States
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Atossa Therapeutics, Inc.

Completed

AT-301 Nasal Spray in Healthy Adults

Healthy

Australia
Biosplice Therapeutics, Inc.

Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Drug-Drug Interaction

United States
Sorrento Therapeutics, Inc.

Withdrawn

Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

Covid-19
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Vitiligo

United States
Impact Therapeutics, Inc.

Unknown

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (SABRINA)

Ovarian Cancer

China
miRagen Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

Chronic Lymphocytic Leukemia (CLL) | Cutaneous T-cell Lymphoma (CTCL) | Mycosis Fungoides (MF) | Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype | Adult T-Cell Leukemia/Lymphoma (ATLL)

United States
Intrepid Therapeutics, Inc.

Completed

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

Acne Vulgaris

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Cara Therapeutics, Inc.

Completed

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

Arthritis | Joint Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Osteoarthritis, Knee | Osteoarthritis, Hip

United States
ImmunoMet Therapeutics, Inc.

Completed

Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

Advanced Solid Tumor

Korea, Republic of
Aclaris Therapeutics, Inc.

Terminated

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Iconic Therapeutics, Inc.

Completed

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

Uveal Melanoma | Choroid Neoplasm

United States
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

Healthy Volunteers

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Cidara Therapeutics Inc.

Completed

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Emergo Therapeutics, Inc.

Completed

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Allergic Rhinitis | Allergic Rhinoconjunctivitis

United States
G1 Therapeutics, Inc.

Completed

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

Spain, United States, Georgia, France, Moldova, Republic of, Hungary, Poland
Palvella Therapeutics, Inc.

Unknown

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Pachyonychia Congenita

United States
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Asthma

United States
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France
Aileron Therapeutics, Inc.

Completed

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Tumor | Peripheral T-Cell Lymphoma

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
Aristea Therapeutics, Inc.

Completed

A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

Inflammatory Response

United Kingdom
Esperion Therapeutics, Inc.

Completed

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk (CLEAR Wisdom)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

United States
Esperion Therapeutics, Inc.

Completed

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Hyperlipidemias

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)

Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | Statin Adverse Reaction

United States, Canada
Mirati Therapeutics Inc.

Completed

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Hungary, United Kingdom, Italy, Australia, Taiwan, Poland, Canada
Cara Therapeutics, Inc.

Completed

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Healthy

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
BioAegis Therapeutics Inc.

Completed

A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP

Community-acquired Pneumonia

Australia, Georgia

3

Subscribe